Ipamorelin Reconstitution Calculator
Turn a target dose you already have into the exact injection volume and insulin syringe units for your vial. The math only. It never picks a dose for you.
An ipamorelin dosage calculator can sound like a tool that tells you what to inject. This one does not. What number to use, and whether to use it at all, is a decision for a licensed prescriber who knows your history. Once you already have a target number from your own protocol or supplier, this calculator converts it into a concentration, a volume in millilitres, and U-100 syringe units. Ipamorelin has no established human dose, so the target dose slider below starts at zero and calculates nothing until you drag it to the number you bring to it.
Enter your own numbers
The target dose slider starts at zero, so nothing here reads as a suggestion for you. Ipamorelin has no established human dose. Drag it to the number from your own protocol source.
Target dose from your protocol or supplier. The slider starts at zero, with no dose recommended, standard, or assumed. Drag it to your own number and the math updates as you set it.
What the evidence and the community report
These are amounts recorded in published studies and registry records, copied exactly as each source states them and never converted. The Who column says where each figure came from, and full citations sit in Sources at the bottom.
A. Approved label doses
None. No regulator has approved this compound, so no label sets a figure for it.
B. Amounts administered in published studies
Every human figure here is intravenous and hospital given. No human subcutaneous amount exists in the published record.
| Amount | Schedule | Route | Who | Ref |
|---|---|---|---|---|
| 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg | infused over 15 minutes | IV infusion | human, n=8 per dose level | PMID 10496658 |
| 0.03 mg/kg | twice daily, postop day 1 to 7 | IV infusion | human, n=117 (114 analysed) | PMID 25331030 |
| 0.03 mg/kg, 0.06 mg/kg | 0.03 twice daily; 0.06 twice or three times daily | intravenous | human, n=320 | NCT01280344 |
C. Community reported practice
Not reprinted here: those subcutaneous schedules are self-reported, not peer reviewed, and the most circulated guide earns commission on sales of the compound.
Disclaimer: no figure here is a recommendation, and per-kilogram or hospital intravenous amounts do not convert into a subcutaneous dose.
Two worked math examples
Both examples use 200 mcg because it is a round number that keeps the arithmetic easy to follow. It is not a recommendation and not a dose to take. Use the figure your own protocol source specifies.
Example A: 5 mg vial with 2 mL
Math illustration, not a dose to take. The concentration is 5 / 2 = 2.5 mg/mL, or 2500 mcg/mL. A 200 mcg target gives 200 / 2500 = 0.08 mL, which is 8 units on a U-100 syringe. The vial contains 5000 / 200 = 25 illustrative draws.
Example B: 10 mg vial with 2 mL
Math illustration, not a dose to take. The concentration is 10 / 2 = 5 mg/mL, or 5000 mcg/mL. A 200 mcg target gives 200 / 5000 = 0.04 mL, which is 4 units on a U-100 syringe. The vial contains 10000 / 200 = 50 illustrative draws.
The target number stays the same in both examples, while the vial amount changes the concentration and syringe reading. Enter your own numbers above to run the same calculation.
What this calculator does, and what it will not do
A reconstitution calculator answers a mechanical question. You have a vial of freeze dried peptide and add a known volume of water. That fixes the concentration. From there, any target number you enter has one matching draw volume, and the calculator finds it. There is no judgment in that step, only division.
What it will not do is choose the dose. A tool that reads your weight or goals and hands back "inject this much" is giving medical advice, and this calculator does not do that. The target dose is something you bring to the calculator, not something it gives you. If you do not have a number from a licensed prescriber or a protocol source you trust, no calculation on this page can supply one.
How to reconstitute an ipamorelin vial
If your vial contains lyophilized powder, reconstitution means adding the water volume you entered above and letting the powder dissolve. These are general vial-handling steps, not instructions for choosing or administering a dose.
- Wipe both rubber stoppers, the peptide vial and the water vial, with an alcohol swab and let them dry.
- Draw the water volume you entered in the calculator into a syringe.
- Insert the needle at a slight angle so the water runs down the inside wall of the vial rather than directly onto the powder.
- Inject the water slowly. Do not shake the vial. Swirl gently until the solution is clear.
- Label the vial with the date and the calculated concentration in mg/mL.
- Follow the supplier's written storage and handling instructions.
Water choice and storage sit outside the calculator's arithmetic. For the difference between the two common water types, see bacteriostatic water vs sterile water. For a general mixing walkthrough, see how to use peptides.
Picking the BAC water volume
The amount of water you add does not change how much peptide is in the vial. It changes the concentration and therefore the liquid volume for the target number you enter. A 5 mg vial reconstituted with 1 mL is twice as concentrated as the same vial with 2 mL, so the draw is half the volume for the same target. More water spreads the syringe marks out, while less water concentrates the draw. The calculator recomputes instantly so you can compare volumes and use the written instructions that came with your vial.
Reading the insulin syringe
The calculator uses the U-100 conversion:
1 unit = 0.01 mL
100 units = 1 mL = full 1 mL barrel
A result of 0.5 mL is 50 units, and a result of 0.25 mL is 25 units. The calculator shows both formats so you can match the volume to a U-100 syringe. It also checks the result against the selected 0.3 mL, 0.5 mL, or 1.0 mL barrel capacity.
Why the calculator does not choose a dose
The published record below includes animal and in-vitro research, a human IV pharmacokinetic study, and a Phase 2 efficacy trial for postoperative ileus. The human efficacy trial did not outperform placebo, and none of these papers establishes a target for self-administered reconstitution. Those sources do not give a calculator a basis for selecting a dose.
The sources are included to explain that boundary, not to turn the calculator into a compound explainer. For information about the compound itself, read the ipamorelin compound profile.
Sources
1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. PMID: 9849822. DOI: 10.1530/eje.0.1390552.
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. PMID: 10496658. DOI: 10.1023/a:1018955126402. Healthy male volunteers, dose escalation, 8 subjects at each of the 5 dose levels; figures reported in nmol/kg and left unconverted here.
3. Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014 Dec;29(12):1527-34. PMID: 25331030. DOI: 10.1007/s00384-014-2030-8. Registered as NCT00672074; 117 enrolled, 114 in the safety and modified intent to treat populations, and the trial did not meet its efficacy endpoints.
4. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009 Jun;329(3):1110-6. PMID: 19289567. DOI: 10.1124/jpet.108.149211.
5. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-55. PMID: 27186127. DOI: 10.2147/JEP.S35396.
6. Phase II double-blind placebo-controlled dose finding study of ipamorelin in patients recovering gastrointestinal function following small or large bowel resection. Sponsor Helsinn Therapeutics. Status COMPLETED, 320 enrolled per the record. Registry record NCT01280344, the larger dose finding sibling of NCT00672074.
Frequently asked questions
Is there a standard ipamorelin dose?
No established human dose appears in the published sources on this page. The human studies used IV infusions for gut-motility and pharmacokinetic endpoints, which are not a template for self-administration. Any dose decision belongs with a licensed prescriber. The target dose slider starts at zero, because the calculator has no number of its own to put there. You drag it to the figure your own protocol source specifies.
How do I use this calculator for my own target dose?
The target dose slider starts at zero and nothing calculates until you move it. Drag it to the number your own protocol or supplier specifies, in mcg or mg, and the calculator recomputes the injection volume, insulin syringe units, and how many doses the vial holds. It never judges the number you set. It only does the arithmetic. For the same math without a compound preset, use the general peptide reconstitution calculator.
How much BAC water do I add to a 5 mg ipamorelin vial?
There is no single answer from the calculator because water volume is a readability choice, not a potency choice. A 5 mg vial in 2 mL of water gives a concentration of 2.5 mg/mL. The same vial in 1 mL gives 5 mg/mL, so whatever target you enter draws half the volume at the higher concentration. More water spreads the marks out on the syringe, less water concentrates the draw, and neither changes how much peptide is in the vial.
Does ipamorelin burn fat or build muscle?
No human study in the listed sources shows either. A human pharmacokinetic study measured a short growth hormone response after IV infusion, but it did not assess body fat or lean mass. The completed human efficacy trial studied postoperative ileus and did not beat placebo on its primary or secondary endpoints.
Is ipamorelin FDA-approved or clinically proven?
The sources on this page do not establish either claim. The completed Phase 2 efficacy trial did not outperform placebo, and none of the listed papers establishes a human dose for body composition or wellness. The target dose slider therefore starts at zero, because there is no approved or standard figure for it to start from. Whatever it shows is a number you set yourself.
Is ipamorelin really side-effect-free because it is "selective"?
The selectivity finding is narrow. In animal and in-vitro work, ipamorelin released growth hormone without significantly raising ACTH or cortisol. That is not the same as having no side effects in humans. The human efficacy trial reported treatment-emergent adverse events in most of the ipamorelin group, so the animal selectivity result is not a human safety guarantee.
Is this calculator medical advice?
No. It is harm reduction education. It performs reconstitution arithmetic on numbers you supply. It does not diagnose, does not prescribe, and does not tell you what dose to take. Dose and schedule are a prescriber decision. Always cross-check with your protocol source, supplier instructions, and where possible a qualified clinician.
This is harm reduction education, not medical advice
This calculator is for educational use. It converts a dose you already have into a volume and syringe reading. It does not choose a dose. Peptide protocols vary between individuals and compounds. Always cross-check with your protocol source, supplier instructions, and where possible a qualified clinician.